Guiyang Xintian Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.00%

Guiyang Xintian Pharmaceutical Co Ltd (002873) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 002873 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥89.77K

≈ $13.14K USD Cash + Short-term Investments

Total Assets

CN¥2.09 Billion

≈ $306.09 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Guiyang Xintian Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002873 equity to assets ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Guiyang Xintian Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Guiyang Xintian Pharmaceutical Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥89.77K	0.0%
Total Liquid Assets	CN¥89.77K	0.00%

Asset Resilience Insights

Limited Liquidity: Guiyang Xintian Pharmaceutical Co Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Guiyang Xintian Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guiyang Xintian Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Guiyang Xintian Pharmaceutical Co Ltd (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Guiyang Xintian Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.00%	CN¥96.87K ≈ $14.18K	CN¥2.12 Billion ≈ $310.38 Million	0.00pp
2024-12-31	0.01%	CN¥118.68K ≈ $17.37K	CN¥1.95 Billion ≈ $285.42 Million	+0.00pp
2023-12-31	0.00%	CN¥94.33K ≈ $13.80K	CN¥1.91 Billion ≈ $279.76 Million	0.00pp
2022-12-31	0.01%	CN¥111.58K ≈ $16.33K	CN¥1.84 Billion ≈ $269.81 Million	-5.24pp
2021-12-31	5.25%	CN¥80.00 Million ≈ $11.71 Million	CN¥1.52 Billion ≈ $223.07 Million	-2.43pp
2020-12-31	7.68%	CN¥118.00 Million ≈ $17.27 Million	CN¥1.54 Billion ≈ $224.76 Million	--

pp = percentage points

About Guiyang Xintian Pharmaceutical Co Ltd

SHE:002873 China Biotechnology

Market Cap

$276.83 Million

CN¥1.89 Billion CNY

Market Cap Rank

#15312 Global

#4507 in China

Share Price

CN¥7.75

Change (1 day)

-0.26%

52-Week Range

CN¥7.75 - CN¥15.19

All Time High

CN¥103738.98